Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM....

Descripción completa

Detalles Bibliográficos
Autores principales: Capra, Marcelo, Martin, Thomas, Moreau, Philippe, Baker, Ross, Pour, Ludek, Min, Chang-Ki, Leleu, Xavier, Mohty, Mohamad, Segura, Marta Reinoso, Turgut, Mehmet, LeBlanc, Richard, Risse, Marie-Laure, Malinge, Laure, Schwab, Sandrine, Dimopoulos, Meletios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Plasma Cell Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152981/
https://www.ncbi.nlm.nih.gov/pubmed/34647444
http://dx.doi.org/10.3324/haematol.2021.279229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152981/
https://www.ncbi.nlm.nih.gov/pubmed/34647444
http://dx.doi.org/10.3324/haematol.2021.279229

Ejemplares similares